PSA Biochemical Recurrence After Prostatectomy and Radiotherapy

After Radical Prostatectomy

The American Urological Association recommends salvage radiotherapy as the primary treatment for PSA biochemical recurrence after prostatectomy without distant metastases, ideally initiated at the earliest sign of PSA recurrence and at the lowest possible PSA level (preferably <0.5 ng/mL) to maximize disease control and reduce prostate cancer-specific mortality 1, 2
Biochemical recurrence is defined as a confirmed PSA ≥0.2 ng/mL with a second confirmatory level ≥0.2 ng/mL, according to the National Comprehensive Cancer Network 1, 3, 4
Re-staging evaluation should be considered to determine if recurrence is local versus metastatic, as this guides salvage strategy selection, with imaging yield being extremely low when PSA is <10 ng/mL, particularly for bone scans 1, 5
Pelvic imaging should be obtained unless the disease is low-volume and low-risk (PSA <1.0, Gleason score <7, and PSA doubling time >15 months), as recommended by the European Association of Urology 6, 7
Salvage radiotherapy should be offered to all patients with PSA or local recurrence after radical prostatectomy who have no evidence of distant metastatic disease, with a minimum dose of 64-66 Gy delivered to the prostatic bed 1, 5, 8
Patients receiving radiotherapy at PSA <0.5 ng/mL achieve 6-year biochemical progression-free survival of 48%, compared to only 18% when PSA is >1.5 ng/mL, according to the American Society of Clinical Oncology 8, 2
Achieving undetectable PSA after salvage radiotherapy is an independent predictor of favorable outcome, with evidence suggesting salvage radiotherapy may reduce prostate cancer-specific mortality, with greatest benefit in patients with PSA doubling time <6 months 8, 2

After Primary Radiotherapy

Biochemical recurrence after radiotherapy is defined as nadir PSA plus 2 ng/mL (Phoenix definition), according to the National Comprehensive Cancer Network 8, 2, 4
The optimal treatment of biochemical relapse after radical radiotherapy is not well-established, and radical local salvage treatments may induce considerable toxicity, as stated by the European Association of Urology 6, 7
Further workup is indicated for patients who are candidates for local therapy, including prostate biopsy, bone scan, and additional imaging as clinically indicated (CT, MRI), as recommended by the National Comprehensive Cancer Network 9
Salvage prostatectomy, cryotherapy, or brachytherapy may be considered for patients with positive biopsy, with treatment individualized based on risk of progression, likelihood of success, and therapy-related risks, according to the American Urological Association 9

Prognostic Factors

Key factors predicting poor response to salvage therapy include Gleason score 8-10, pre-salvage PSA >2 ng/mL, negative surgical margins, PSA doubling time <10 months, and seminal vesicle invasion, as identified by the National Comprehensive Cancer Network 8, 2, 9
Patients without these adverse features achieve 6-year progression-free survival of 69% with salvage radiotherapy, according to the American Society of Clinical Oncology 8, 2

Management of Biochemical PSA Relapse After Radical Prostatectomy and Radiotherapy

Introduction to Guidelines

The European Society for Medical Oncology (ESMO) recommends against routine early androgen deprivation therapy (ADT) for men with prostate cancer who have biochemical relapse unless they have symptomatic local disease progression, proven metastases, or PSA doubling time <3 months 10, 11, 12.

Evidence Against Routine Early ADT

Retrospective series evaluating ADT for relapse following radical prostatectomy or radiotherapy observed no survival benefit, although time to clinical metastases was delayed by early androgen treatment 10, 11.
The PR.7 trial (1386 patients) comparing intermittent versus continuous ADT in biochemical relapse showed median overall survival of 8.8 versus 9.1 years respectively (HR 1.02; 95% CI 0.86-1.21), demonstrating no survival advantage for ADT initiation 10, 11, 13.

Clinical Context and Recommendations

The National Comprehensive Cancer Network (NCCN) guidelines note that most patients with biochemical failure will have a good 15-year prognosis, with outcomes best approximated by absolute PSA level, PSA doubling time, and initial disease characteristics 13.
ADT should be considered selectively based on specific high-risk features rather than routinely initiated 10, 12, 14, 15.

High-Risk Indicators for Earlier ADT Consideration

PSA doubling time <3 months 10, 16, 11, 12.
PSA doubling time <6-12 months with long life expectancy 13, 14, 15.
Symptomatic local disease progression 10, 16, 11, 12.
Proven metastatic disease 10, 16, 11, 12.
Baseline PSA >50 ng/mL 14, 15.

Quality of Life Considerations

Intermittent ADT is recommended over continuous ADT based on Level I evidence 10, 16, 11, 12.
The PR.7 trial demonstrated that intermittent ADT was non-inferior to continuous ADT for overall survival while providing superior quality of life in multiple domains including physical function, fatigue, urinary problems, hot flashes, libido, and erectile dysfunction 13.

Common Pitfalls to Avoid

Do not initiate ADT reflexively based solely on rising PSA after both prostatectomy and radiotherapy have been completed 10, 11.
Early ADT delays time to metastases but does not improve overall survival 10, 11.
Patient anxiety about rising PSA should not drive treatment decisions 13.
The cumulative toxicity of ADT significantly impacts quality of life without survival benefit in most patients 16, 13.

Management of Biochemical Recurrence After Radiotherapy for Prostate Cancer

Defining Biochemical Recurrence

The American Urological Association defines biochemical recurrence after radiotherapy as nadir PSA plus 2 ng/mL (Phoenix definition), which is the standard criterion used to identify treatment failure 17
A consistently rising PSA usually, though not always, indicates cancer recurrence, and the time of failure should not be backdated to the first PSA rise 17

Restaging Evaluation

The European Association of Urology recommends PSMA PET/CT as the most sensitive imaging modality to detect metastases in patients with biochemical recurrence and should be the preferred restaging tool 18
Conventional imaging (bone scan, CT) has extremely low yield when PSA is below 10 ng/mL 19, 17

Salvage Local Therapy Options

The European Urology guidelines suggest that salvage local therapies, such as cryotherapy, may be considered for patients with biopsy-proven local recurrence and no evidence of distant metastatic disease 18
Salvage cryotherapy can be used as a salvage treatment option after radiation failure, with main adverse effects including erectile dysfunction, urinary incontinence, urethral sloughing, rectal pain and bleeding, and rectourethral fistula formation 18

Systemic Therapy Considerations

The National Comprehensive Cancer Network recommends that routine early androgen deprivation therapy (ADT) is NOT recommended for men with biochemical relapse unless they have symptomatic local disease progression, proven metastases, or PSA doubling time <3 months 18
Salvage local therapies carry substantial morbidity and should only be offered to carefully selected patients with confirmed local-only disease 18

Management of Biochemical Recurrence After Radiation Therapy for Prostate Cancer

Diagnostic Approach

The European Association of Urology recommends proceeding with confirmatory biopsy of the prostate and PSMA PET/CT imaging to confirm local-only recurrence, followed by consideration of focal salvage therapy if truly isolated intraprostatic disease is confirmed 20, 21
A patient meets the Phoenix criteria for biochemical recurrence, with PSA rise of ≥2 ng/mL above nadir, and PSA monitoring is essential for diagnosis 20, 21, 22
The European Urology Oncology guidelines suggest that MRI finding of a PIRADS 5 lesion strongly suggests local recurrence, but tissue confirmation is essential before proceeding with salvage therapy 20, 21

Restaging Workup

The European Urology Oncology guidelines recommend PSMA PET/CT as the preferred imaging modality for restaging, as it is far more sensitive than conventional imaging for detecting occult metastatic disease at these PSA levels 20, 21
Conventional bone scans and CT have extremely low yield when PSA is below 10 ng/mL and should not be relied upon, according to the Journal of Urology 23
A negative PET scan is reassuring, but confirmation that it was a PSMA PET rather than conventional imaging is necessary 20, 21

Treatment Decision

The European Urology Oncology guidelines state that prostate biopsy is mandatory to confirm local recurrence and re-establish the Gleason grade, as this critically impacts treatment decisions 20, 21
Multiple radiographic and tissue sampling modalities should concordantly confirm focal recurrence before pursuing focal salvage therapy, as recommended by the European Urology Oncology 20
Salvage local therapy should be offered if biopsy shows grade upgrading (Gleason ≥7), with options including salvage cryotherapy, salvage brachytherapy, or salvage radical prostatectomy 20, 21
Focal salvage approaches (cryotherapy or stereotactic radiotherapy) are preferred when confidence in focal recurrence is confirmed via concordant imaging and biopsy, according to the European Urology Oncology guidelines 20, 21
Short-duration hormonal therapy (≤6 months) may be beneficial for radiosensitization when pursuing salvage radiotherapy, using classic androgen deprivation rather than novel hormonal agents, as suggested by the European Urology Oncology 20

Critical Prognostic Factors

None of the critical prognostic factors mentioned have associated citations, therefore no information can be provided.

Common Pitfalls to Avoid

Inadequate pre-salvage staging, proceeding with salvage local therapy without PSMA PET/CT, risks treating patients with occult metastatic disease who would not benefit, according to the European Urology Oncology guidelines 20, 21
Using conventional imaging, such as bone scans and CT, has extremely low yield at PSA <10 ng/mL and will miss occult disease, as stated in the Journal of Urology 23